A recent JAMA review highlights updated strategies for managing type 2 diabetes, stressing the importance of personalized treatment based on individual risk factors and comorbidities. With type 2 diabetes constituting 90-95% of diabetes cases globally, early use of SGLT2 inhibitors and GLP-1 receptor agonists is recommended, especially for patients with cardiovascular disease, heart failure, or chronic kidney disease. The review emphasizes the role of lifestyle modifications and innovative treatments like continuous glucose monitoring to optimize glycemic control and minimize complications.

Source: JAMA